Back to results
US 2024/0200075 A1Published application
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsWilliam Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin A. Maier
Life of this patent
Estimating the term…
Abstract
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
Claims26
A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of angiopoietin-like 3 (ANGPTL3),
- wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, the antisense strand comprising at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences listed in any one of Tables 2A, 2B, 4A, 4B, 5, 7A, 7B, 7C, 8A, 8B, 10A, 10B, 13A, 13B, 14, 15A, and 15B.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-21. (canceled)
Dependencies are inferred from the claim text.